Jun 1, 2025, 17:44

Notice of Special Interest: Research Projects to Develop Oncoaging Models for Cancer Research

The National Cancer Institute (NCI) and National Institute on Aging (NIA) invite applications to establish or improve cancer models that integrate age-related biological changes. These “oncoaging” models should recapitulate how aging influences tumor initiation, progression, and treatment response, enabling mechanistic and translational studies relevant to older adults with cancer.

Eligibility Criteria:

Any U.S. or foreign higher education institution, nonprofit research organization, or for-profit entity eligible to submit under the chosen parent FOA (e.g., R01, R21).
Principal Investigator must possess appropriate credentials and experience in cancer biology, aging research, or allied fields.
Proposed project must address one or more aims listed in the NOSI, such as developing or validating preclinical oncoaging models or elucidating mechanistic links between aging hallmarks and tumor biology.
Applicants cannot submit applications that ignore the biological context of aging or focus solely on cancer risk/prevention without modeling age-related changes.

Funding Details:

Mechanisms: Submit under one of the following parent FOAs (or their reissues) through July 31, 2027:
- PA-20-185 (R01 Clinical Trial Not Allowed)
- PA-20-195 (R21 Clinical Trial Not Allowed)
- PAR-22-216 (R21 Clinical Trial Optional)
- PAR-22-099 (R01 Clinical Trial Optional)
- PAR-23-281 (R01 Clinical Trial Not Allowed)
Budget & Duration: Follow the parent announcement’s instructions for budget caps and project periods (typically up to 5 years for R01; up to 2 years for R21).
Inclusion of “NOT-CA-23-092”: Must enter “NOT-CA-23-092” in Agency Routing Identifier box 4B of the SF424 (R&R) form to ensure consideration under this NOSI.

Deadline:

All parent FOA due dates through July 31, 2027 (expiration date).

Where to Go for Further Information:

NOSI Text
Contact NCI Scientific Inquiry:
- Margaret Klauzinska, Ph.D. ([email protected])
- Weiwei Chen, Ph.D. ([email protected])
Contact NIA Scientific Inquiry:
- Max Guo, Ph.D. ([email protected])

aging cancer cancer models GeroScience NCI NIA NIH oncoaging OncoDaily Oncology organoids Preclinical models translational research tumor microenvironment xenografts

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening